Home › Trial NCT04023110
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
- Trial IDNCT04023110
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorAbramson Cancer Center at Penn Medicine
- Enrollment68
- Start date2019-08-09
- ConditionsCardiotoxicity · Risk Factor, Cardiovascular · Toxicity Due to Chemotherapy · Breast Cancer · Cardiomyopathies · Heart Failure
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.